Pegvisomant: current and potential novel therapeutic applications

Expert Opinion on Biological Therapy
G N Ajay ThankamonyCarlo L Acerini

Abstract

Pegvisomant is a genetically engineered molecule, which exhibits specific growth hormone (GH) antagonism by directly interacting with the GH receptor. It is currently licensed for the treatment of acromegaly where surgery and medical therapy with somatostatin analogues have failed. To delineate the role of pegvisomant in the treatment of acromegaly and its novel application in other areas of clinical medicine where suppression of GH action may be of therapeutic benefit. A literature review from PubMed- and EMBASE-listed publications and the web-sites of licensing organisations for medicinal products. Pegvisomant is currently used as a second line therapy in the management of acromegaly. It is highly effective in suppressing the metabolic effects of elevated GH levels when used alone or in combination with somatostatin analogues. However, its long term efficacy and safety for this indication has yet to be established. Preliminary data indicate that pegvisomant may have a role in management of type 1 diabetes with beneficial effects on insulin sensitivity and in preventing the progression of microvascular complications. Additional roles as an adjunct to cancer chemotherapy regimens and for the diagnosis of GH deficiency have been...Continue Reading

References

Jun 1, 1978·The New England Journal of Medicine·T J Merimee
Jul 1, 1992·European Journal of Clinical Investigation·R P DullaartW J Sluiter
May 1, 1992·Archives of Disease in Childhood·D B Dunger
Feb 20, 1991·JAMA : the Journal of the American Medical Association·O SerriL Vachon
Jun 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·A Flyvbjerg
Aug 1, 1990·The American Journal of Physiology·C M Rembold, R A Murphy
Mar 1, 1989·Kidney International·R HirschbergJ D Kopple
Feb 11, 1994·Journal of Molecular Biology·M H UltschA M de Vos
Jul 1, 1997·The Journal of Clinical Endocrinology and Metabolism·J C CarelJ Coste
Apr 20, 2000·The New England Journal of Medicine·P J TrainerR J Davis
Jun 17, 2000·Endocrine Reviews·H M KhandwalaK E Friend
Jan 3, 2001·The Journal of Clinical Endocrinology and Metabolism·N R BiermaszF Roelfsema
Jun 28, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G DahlquistS Rudberg
Aug 21, 2001·Clinical Pharmacokinetics·J M HarrisM Modi
Dec 26, 2001·Ophthalmology·UNKNOWN Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group
Jun 22, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M HejnaM Raderer
Nov 9, 2002·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·D Roderick Rose, David R Clemmons
Jul 28, 2005·The Journal of Clinical Endocrinology and Metabolism·Jens Otto Lunde JørgensenHans Ørskov
Aug 4, 2005·The Journal of Clinical Endocrinology and Metabolism·Ariel L BarkanMary Lee Vance
Aug 23, 2005·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Fernando P DominiciDaniel Turyn
Aug 24, 2005·Nature Structural & Molecular Biology·Richard J BrownMichael J Waters
Dec 24, 2005·Advances in Experimental Medicine and Biology·Laura M Frago, Julie A Chowen

❮ Previous
Next ❯

Citations

Nov 16, 2010·Current Opinion in Oncology·Ranee R Lleva, Silvio E Inzucchi
Apr 24, 2012·Hematology/oncology Clinics of North America·Fernanda I Arnaldez, Lee J Helman
Jun 29, 2013·Current Opinion in Endocrinology, Diabetes, and Obesity·Jo K PerryPeter E Lobie
Jul 29, 2010·Nature Reviews. Endocrinology·Andrew J Brooks, Michael J Waters
Feb 19, 2019·Signal Transduction and Targeted Therapy·Man LuJo K Perry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.